Labcorp Holdings Inc. filings document a public laboratory-services company with common stock listed on the New York Stock Exchange under LH. Its 8-K reports cover operating results, financial guidance, dividend declarations, board appointments, and material definitive agreements tied to financing arrangements.
Labcorp's regulatory record also includes proxy materials describing board composition, committee service, executive compensation, equity awards, shareholder voting matters and governance practices. Debt and liquidity-related filings disclose senior unsecured term-loan terms, receivables purchase arrangements, covenants and related obligations, while earnings exhibits detail results across the company's diagnostics and biopharma laboratory services activities.
LABCORP HOLDINGS INC. director Kerrii B. Anderson reported selling 3,000 shares of common stock on 2026-08-17 at $318.02 per share in an open-market or private transaction made pursuant to a Rule 10b5-1 trading plan. After this sale, she held 6,563 shares directly and 144 shares indirectly in each of two separate trusts.
Labcorp Holdings Inc. (NYSE: LH) reported that it will host an Investor Day on September 10, 2026, from 9 a.m. to noon ET. Chairman and CEO Adam Schechter, CFO Julia Wang and other executives plan to present the company’s go-forward strategy, capital deployment priorities and long-term financial outlook, followed by a Q&A session. A live webcast and subsequent replay with supporting materials will be available via the company’s investor relations website.
Labcorp describes itself as a global leader in laboratory services with nearly 71,000 employees serving clients in approximately 100 countries. It supported more than 85% of new drugs and therapeutic products approved by the FDA in 2025 and performed more than 750 million tests for patients worldwide.
Labcorp Holdings Inc. reports a leadership change in its laboratory services business. On August 11, 2026, Megan D. Bailey notified the company of her decision to resign as Executive Vice President and President, Central Laboratories and International, effective September 4, 2026.
Effective September 1, 2026, Brian J. Caveney, M.D., currently Executive Vice President and President, Early Development Research Laboratories and Chief Medical and Scientific Officer, will assume the role of Executive Vice President and President, Biopharma Laboratory Services and Chief Medical and Scientific Officer. In this expanded role, he will oversee both the Early Development Research Laboratories and Central Laboratories businesses.
LABCORP HOLDINGS INC. President & CEO Adam H. Schechter reported a sale of common stock. On 2026-08-11, he sold 4,669 shares of Labcorp common stock at a price of $320.37 per share in an open-market or private transaction. After this transaction, he directly holds 102,565 shares of common stock. The sale was executed pursuant to a pre-established trading plan in accordance with Rule 10b5-1 under the Securities Exchange Act of 1934.
Adam Schechter filed to sell common stock of LH under Rule 144. The planned sale covers 4,669 shares of common stock through Fidelity Brokerage Services LLC, with an indicated value of $1,495,807.53, to be sold on the NYSE on or after August 11, 2026.
The shares to be sold were acquired from the issuer on March 27, 2024 via Restricted Stock Vesting as compensation in the amount of 4,669 shares. The filing also reports that during the past three months, on May 11, 2026, 5,903 shares of common stock were sold for $1,502,313.50.
Amy B. Summy, EVP and Chief Marketing Officer of Labcorp Holdings Inc., reported a sale of 924.0000 shares of Common Stock on 2026-08-04 at $306.7400 per share in a sale classified as an open-market or private transaction. After this sale, she directly owns 6955.5000 shares.
Labcorp Holdings Inc. senior vice president and chief accounting officer Peter J. Wilkinson exercised 1,338 non-qualified stock options at an exercise price of $209.25 per share, receiving 1,338 common shares. On the same date he sold 1,420 common shares in open-market transactions at prices of $309.22 and $309.2311 per share. The specific option grant, issued under Labcorp's Amended and Restated 2016 Omnibus Incentive Plan, is now fully exercised.
A holder of LH common stock has notified an intention to sell 924 shares of common stock through Fidelity Brokerage Services LLC on or after August 4, 2026, with an indicated aggregate market value of $283,427.76 on the NYSE.
The shares to be sold were acquired from the issuer through a series of transactions, including restricted stock vesting events on February 7, 2024, February 6, 2025, February 7, 2025, and February 11, 2025, and a stock option exercise on November 22, 2024, characterized as compensation and cash transactions.